Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Nivolumab 11pembrolizumab 10Ipilimumab 9Cyclophosphamide 6tebentafusp 5Interleukin-2 4Blood Specimen Collection 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 3Melphalan 3Magnetic Resonance Spectroscopy 3relatlimab 2lenvatinib 2cemiplimab 2binimetinib 2aflibercept 2Surveys and Questionnaires 2Dacarbazine 2Crizotinib 2Carmustine 2Biopsy 2ulixertinib 1trametinib 1sargramostim 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Epilim × 1 year × Clear all
NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Thomas Jefferson University

Phase 2 Active not recruiting
210 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡